Investor Presentation July 31, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe, ...

Company Vision and Strategy - Omnicell's mission is to be the care provider's most trusted partner, with a vision to accelerate pharmacy to perfection[10, 35] - The company aims to execute on the vision of a fully Autonomous Pharmacy, leveraging cloud technology to transform pharmacy care delivery[36, 116] - Omnicell differentiates itself through a comprehensive portfolio across the care continuum, serving 50% of US providers[36, 116] Market and Growth Opportunities - Omnicell estimates a total addressable market of $20 billion for Point of Care, $15 billion for Central Pharmacy, and significant opportunities in Retail, Institutional, and Payer segments over 10 years[43, 44] - The company projects revenue growth to $1450-$1550 million by 2024, driven by a ~17% CAGR in Central Pharmacy, ~10%-12% CAGR in Point of Care, and ~10% CAGR in Retail, Institutional, and Payer segments[110, 116] - Omnicell's XT Automated Dispensing Cabinets are early in their replacement cycle, showing 18% progress as of 3Q19[44] Financial Performance and Goals - Omnicell's revenue for 2019 is estimated to be between $889 and $895 million[106, 110, 128] - The company is committed to increasing non-GAAP operating margin to ~18% by 2024[108, 113, 116] - Omnicell targets a free cash flow conversion of 90%-110% of GAAP Net Income[115, 116] Medication Management and Safety - Medication errors lead to significant losses, including $300 billion annually, 1 million ER visits, and 125,000 hospitalizations[15] - A significant percentage of prescriptions, 20%-30%, are never filled, contributing to suboptimal outcomes[15] - Drug diversion costs $72.5 billion, highlighting the need for improved medication management and security[23]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $270 million, an increase of $24 million from Q1 2024, but a decrease of $37 million from Q4 2024 [8][17] - Product revenues were $145 million, up $12 million year-over-year but down $37 million sequentially [9][18] - Service revenues were $125 million, an increase of $12 million from Q1 2024 and flat compared to Q4 2024 [9][18] - Non-GAAP gross margin for Q1 2025 was 42.1%, a decrease of 530 basis points from the prior quarter [9][19] - GAAP earnings per share for Q1 2025 was a loss of $0.15, compared to a loss of $0.34 in Q1 2024 [10][20] - Non-GAAP earnings per share for Q1 2025 was $0.26, compared to $0.03 in the same period last year [10][20] - Non-GAAP EBITDA for Q1 2025 was $24 million, an increase of $13 million year-over-year but a decrease of $23 million from the previous quarter [10][21] Business Line Data and Key Metrics Changes - The XT Amplify program contributed to revenue growth, alongside SaaS and XPath services, including specialty pharmacy services [17][18] - The company continues to see strong customer interest in its long-term innovation roadmap [8][17] Market Data and Key Metrics Changes - The demand environment tracked well with expectations, showing market share gains and continued interest in the product platform [7][8] - Leading health systems in various states have invested in Omnicell solutions to improve efficiency and patient safety [12][14] Company Strategy and Development Direction - The company aims to capture greater market share across inpatient and outpatient settings, grow predictable recurring revenue, and expand its cloud-based platform, Omnisphere [7][8] - The focus remains on redefining medication and supply management across healthcare [6][7] - The company is adapting its supply chain to mitigate tariff impacts, including dual sourcing and near-shoring efforts [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the current tariff environment and emphasized the importance of supply chain optimization [11][15] - The company remains optimistic about long-term growth strategies aligning with the vision of the Autonomous Pharmacy [15][28] - Management noted that the first quarter typically has the lowest revenue and profitability, with expectations for growth throughout the year [20][21] Other Important Information - The anticipated impact from tariffs for 2025 is approximately $40 million to non-GAAP EBITDA, leading to adjustments in guidance [11][26] - Cash and cash equivalents at the end of Q1 2025 were $387 million, up from $369 million at the end of Q4 2024 [21] Q&A Session Summary Question: Can you describe the outlook for tariff distribution between Omnicell and customers? - Management indicated that currently, they are not passing significant price increases to customers but may adjust discounts in the future [32] Question: What is the cadence of the $40 million tariff impact? - The total impact is expected to be $40 million, with about $5 million in Q2 and the remainder in the second half of the year [39][41] Question: Are there any fundamentals driving reacceleration in demand for pharmacy IT? - Management noted that specialty pharmacy is a top topic among providers, leading to more strategic discussions about investments [48][50] Question: What are the assumptions behind the new EBITDA guidance range? - The guidance changes were primarily driven by tariff impacts, with mitigation actions including relocating supply chains and evaluating pricing [54][59] Question: How long will it take to disintermediate supply chain exposure to China? - Management stated that while some components will still flow through China, they are taking actions to move sourcing to other regions over time [66] Question: How does the hospital buying environment look currently? - Management reported no slowdown in revenue or installation processes, indicating a positive environment despite potential macroeconomic challenges [86]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $270 million, an increase of $24 million from Q1 2024, but a decrease of $37 million from Q4 2024 [6][15][19] - Product revenues were $145 million, up $12 million year-over-year but down $37 million sequentially [7][16] - Service revenues were $125 million, an increase of $12 million from the previous year and flat compared to the prior quarter [7][16] - Non-GAAP gross margin for Q1 2025 was 42.1%, a decrease of 530 basis points from the prior quarter [7][16] - Non-GAAP earnings per share for Q1 2025 was $0.26, compared to $0.03 in the same period last year and $0.60 in the prior quarter [8][17] - Non-GAAP EBITDA was $24 million, an increase of $13 million year-over-year but a decrease of $23 million from the previous quarter [8][18] Business Line Data and Key Metrics Changes - The XT Amplify program contributed to revenue growth, alongside SaaS and XPath services, particularly in specialty pharmacy services [15][16] - The company continues to see strong customer interest in its long-term innovation roadmap, particularly in medication management solutions [5][6] Market Data and Key Metrics Changes - The demand environment tracked well with expectations, showing market share gains and continued interest in the company's product offerings [5][6] - The company is focused on expanding its market share across inpatient and outpatient settings, including specialty and retail pharmacies [5][6] Company Strategy and Development Direction - The company aims to capture greater market share in various healthcare settings and grow its predictable recurring revenue [5][6] - The strategy includes expanding the Omnisphere cloud-based platform and integrating AI technologies across the continuum of care [5][6] - The company is committed to optimizing its supply chain and mitigating tariff impacts through dual sourcing and near-shoring efforts [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the current tariff environment and emphasized the importance of supply chain optimization [9][13] - The company remains optimistic about long-term growth strategies aligning with the vision of the Autonomous Pharmacy [13][27] - Management noted that the first quarter typically has the lowest revenue and profitability, with expectations for growth throughout the year [17][19] Other Important Information - The anticipated impact from tariffs for 2025 is approximately $40 million to non-GAAP EBITDA, leading to adjustments in guidance [9][24] - The company continues to generate solid free cash flow, with cash and cash equivalents at $387 million as of Q1 2025 [19][20] Q&A Session Summary Question: Can you describe the outlook for tariff distribution between Omnicell and customers? - Management indicated that currently, they are not passing significant price increases to customers but may adjust discounts in the future [30][31] Question: What is the cadence of the $40 million tariff impact? - The total impact is expected to be $40 million for the year, with about $5 million in Q2 and the remainder in the second half, particularly in Q4 [36][38] Question: Are there any fundamentals driving reacceleration in demand for pharmacy IT? - Management noted that specialty pharmacy is a top topic among providers, leading to more strategic discussions about revenue generation and operational efficiency [45][47] Question: What are the assumptions behind the new EBITDA guidance range? - The guidance changes account for tariffs, with mitigation actions including relocating supply chains and evaluating pricing strategies [52][56] Question: How long will it take to reduce supply chain exposure to China? - Management stated that while some components will still flow through China, they are taking actions to move sourcing to other regions over time [63][64] Question: How is the hospital buying environment characterized? - Management reported no slowdown in revenue or installation processes, indicating a positive environment despite potential macroeconomic challenges [80][84]

Investor Presentation May 6, 2025 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical information. Without limiting the foregoing, statements including the words "expect," "intend," "may," "will," "should," "would," "could," "plan," "potential," "anticipate," "believe," ...